Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Oncogene. 2018 Mar 15;37(23):3151–3165. doi: 10.1038/s41388-018-0178-3

Figure 6. miR-21 downregulates JAK2 and STAT1 to suppress IFN-γ-mediated STAT1 signaling.

Figure 6

(a) Putative miR-21 binding sites within the 3′UTRs of STAT1 and JAK2. The matching sites are indicated by the vertical lines. (b) Activity of luciferase reporters containing wild type (WT) or mutant (Mut) miR-21 target sites in the STAT1 3′UTR. (c) mRNA levels of Stat1 and Jak2 in WT and miR-21−/− BMDMs. *P ≤ 0.05, **P ≤ 0.01, n.s., not significant. (d and e) Immunoblotting analysis of protein levels of JAK1, JAK2, phosphorylation of STAT1 on tyrosine 701 (pSTAT1), STAT1, PDCD4, and actin in BMDMs (d) and MEFs (e). (f and g) Immunoblotting analysis of protein levels of pSTAT1, STAT1, PDCD4 and actin in miR-21−/− MEFs transfected with miR-21 (f) or in WT MEFs transfected with a locked nucleic acid miR-21 inhibitor (g) and treated with IFN-γ (20 ng/mL) for up to 60 min. (h) Immunoblotting analysis of protein levels of phospho-IKKα/β, phospho-p65, phospho-IκB, and total IκB in WT and miR-21−/− BMDMs upon LPS (50 ng/mL) stimulation for the indicated times. (i) Immunoblotting analysis of protein levels of pSTAT6, STAT6, PDCD4, and actin in WT and miR-21−/− BMDMs upon stimulation with IL-4 (10 ng/mL) for indicated times.

HHS Vulnerability Disclosure